Overview

• In its Phase 2 trial, monthly MariTide injections produced up to 20% weight loss in patients with obesity alone and up to 17% in those with type 2 diabetes, versus under 3% for placebo groups.
• Trial results showed reductions of as much as 2.2 percentage points in hemoglobin A1c; participants also saw lower blood pressure, inflammation markers and cholesterol levels.
• Gastrointestinal events such as nausea and vomiting were common but became less frequent when dosing began at lower levels with gradual escalation, prompting Amgen to revise its regimen.
• MariTide’s design couples a GLP-1 receptor agonist with a GIP receptor antagonist on a monoclonal antibody backbone, enabling extended monthly dosing.
• The upcoming 72-week Phase 3 trial will randomize participants to three dosing arms; additional studies are planned for patients with cardiovascular disease, heart failure or obstructive sleep apnea.